Gout Agents WA.PHAR.40 Gout Agents - Coordinated Care
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Gout Agents
WA.PHAR.40 Gout Agents Effective Date: March 1, 2021
Note: New-to-market drugs included in this class based on the Apple Health Preferred Drug List are non-preferred and subject to this prior
authorization (PA) criteria. Non-preferred agents in this class require an inadequate response or documented intolerance due to severe adverse
reaction or contraindication to at least TWO preferred agents. If there is only one preferred agent in the class documentation of inadequate
response to ONE preferred agent is needed. If a drug within this policy receives a new indication approved by the Food and Drug Administration
(FDA), medical necessity for the new indication will be determined on a case-by-case basis following FDA labeling.
To see the list of the current Apple Health Preferred Drug List (AHPDL), please visit:
https://pharmacy.envolvehealth.com/content/dam/centene/envolve-pharmacy-solutions/pdfs/PDL/FORMULARY-
CoordinatedCare_Washington.pdf
Background:
Gout is a crystalline arthropathy predominantly observed in patients 30 to 50 years old and is more common in men
than in women. Gout is caused by either an over-production or an under-excretion of uric acid. This results in
deposits of monosodium urate crystals in joints and soft tissue. The disease is often, but not always, associated with
increased blood uric acid levels.
Symptoms of gout include recurrent inflammatory arthritis; the development of tophi, and uric acid urolithiasis.
Acute gout most commonly affects the first metatarsal joint of the foot, but other joints may be affected, such as the
small joints of the hands, wrists, and elbows.
Medical necessity
Drug Medical Necessity
Febuxostat (Uloric) Febuxostat and pegloticase may be considered medically necessary when
Pegloticase (Krystexxa) used for the treatment of symptomatic hyperuricemia associated with
gout.
Clinical policy:
Clinical Criteria
Febuxostat (Uloric) Febuxostat, may be covered when ALL of the following are met:
1. Diagnosis of symptomatic hyperuricemia associated with gout
confirmed by ONE of the following:
a. Measurement of blood uric acid levels
b. Measurement of erythrocyte sedimentation rate
c. Polarized light microscopy for identification of crystal in
synovial fluids obtained from joints or bursas (as well as
material aspirated from tophaceous deposits, if any)
d. Magnetic resonance imaging for gouty tophus
2. Is NOT used for the treatment of asymptomatic hyperuricemia
Policy: Gout Agents Last Updated 03/03/2021
13. Greater than or equal to (≥) 3 gout flares in the previous 18 months
that were inadequately controlled by colchicine, corticosteroids, or
non-steroidal anti-inflammatory drugs (NSAIDs), or at least 1 gout
tophus or gouty arthritis
4. Trial and failure (normalize serum uric acid to less than 6 mg/dL) for at
least 3 months, contraindication or intolerance to allopurinol at
maximum tolerated dose
5. Medications known to precipitate gout attacks have been
discontinued/changed when possible
6. Client will NOT be receiving treatment with azathioprine or
mercaptopurine
7. An assessment of cardiovascular risk factors to determine the benefits
and risks associated with beginning febuxostat for the patient. Patient
has been counseled about the cardiovascular risks associated with
febuxostat
If ALL criteria are met, the request will be approved for 12 months
If all criteria are not met, but there are circumstances supported by clinical
judgement and documentation, requests may be approved by a clinical
reviewer on a case-by-case basis up to the initial authorization duration.
Criteria (Reauthorization)
Febuxostat may be reauthorized when ALL of the following are met:
1. Confirmation of a positive clinical response defined as an improvement
in blood uric acid levels, erythrocyte sedimentation rate, polarized light
microscopy, magnetic resonance imaging, or reduction in gout flares
2. Prescriber submits an assessment of cardiovascular risk factors
If ALL criteria are met, the request will be approved for 12 months
If all criteria are not met, but there are circumstances supported by clinical
judgement and documentation, requests may be approved by a clinical
reviewer on a case-by-case basis up to the reauthorization duration.
Pegloticase (Krystexxa) Krystexxa may be covered when ALL of the following are met:
1. Diagnosis of symptomatic hyperuricemia associated with gout
confirmed by ONE of the following:
a. Measurement of blood uric acid levels
b. Measurement of erythrocyte sedimentation rate
c. Polarized light microscopy for identification of crystal in
synovial fluids obtained from joints or bursas (as well as
material aspirated from tophaceous deposits, if any)
d. Magnetic resonance imaging for gouty tophus
Policy: Gout Agents Last Updated 03/03/2021
22. Greater than or equal to (≥) 3 gout flares in the previous 18 months
that were inadequately controlled by colchicine, corticosteroids or non-
steroidal anti-inflammatory drugs (NSAIDs), or the patient has at least 1
gout tophus or gouty arthritis
3. Trial and failure (normalize serum uric acid to less than 6 mg/dL) for at
least 3 months, contraindication or intolerance to allopurinol AND
Uloric at maximum tolerated dose
4. Medications known to precipitate gout attacks have been
discontinued/changed when possible
5. Client does not have history of G6PD deficiency
6. Client will not take oral urate-lowering medications while on Krystexxa
therapy
If ALL criteria are met, the request will be approved for 12 months
If all criteria are not met, but there are circumstances supported by clinical
judgement and documentation, requests may be approved by a clinical
reviewer on a case-by-case basis up to the initial authorization duration.
Criteria (Reauthorization)
Pegloticase may be reauthorized when ALL of the following are met:
1. Confirmation of positive clinical response defined as an improvement
in blood uric acid levels, erythrocyte sedimentation rate, polarized light
microscopy, magnetic resonance imaging, or reduction in gout flares.
If ALL criteria are met, the request will be approved for 12 months
If all criteria are not met, but there are circumstances supported by clinical
judgement and documentation, requests may be approved by a clinical
reviewer on a case-by-case basis up to the reauthorization duration.
Dosage and quantity limits
Drug Dose and Quantity Limits
febuxostat (Uloric) • Symptomatic hyperuricemia associated with gout: MAX 80 mg per
day; #30 tablets for 30-day supply
pegloticase (Krystexxa) • 8 mg (1 mL) infusion every 2 weeks; 26 infusions per year
Coding:
HCPCS Code Description
J2507 Injection, pegloticase, 1 mg
References
1. Uloric [package insert].Takeda Pharmaceuticals NA; Chicago, Illinois; 2009.
Policy: Gout Agents Last Updated 03/03/2021
32. Matsuo H, Yamamoto K, Nakaoka H, et al. Genome-wide association study of clinically defined gout identifies
multiple risk loci and its association with clinical subtypes. Ann Rheum Dis. 2016;75(4):652-659.
3. Dalbeth N, Stamp LK, Merriman TR. The genetics of gout: Towards personalised medicine? BMC Med.
2017;15(1):108.
4. Cleophas MC, Joosten LA, Stamp LK, et al. ABCG2 polymorphisms in gout: Insights into disease susceptibility and
treatment approaches. Pharmgenomics Pers Med. 2017;10:129-142.
5. Becker MA. Clinical manifestations and diagnosis of gout. UpToDate [online serial] Waltham, MA: UpToDate;
reviewed July 2017a.
6. Becker MA. Treatment of acute gout. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed July 2017b.
7. Qaseem A, McLean RM, Starkey M, Forciea MA1; Clinical Guidelines Committee of the American College of
Physicians. Diagnosis of acute gout: A clinical practice guideline From the American College of Physicians. Ann
Intern Med. 2017a;166(1):52-57.
8. Qaseem A, Harris RP, Forciea MA; Clinical Guidelines Committee of the American College of Physicians.
Management of acute and recurrent gout: A clinical practice guideline from the American College of Physicians.
Ann Intern Med. 2017b;166(1):58-68.
9. Son CN, Song Y, Kim SH, et al. Digital tomosynthesis as a new diagnostic tool for assessing of chronic gout arthritic
feet and ankles: comparison of plain radiography and computed tomography. Clin Rheumatol. 2017 Jun 8
10. Becker, M. Clinical manifestations and diagnosis of gout. In: UpToDate, Basow, DS (Ed). UpToDate, Waltham, MA,
2010.
11. Food and Drug Administration; Center for Drug Evaluation and Research; Medical Review for BLA 125293,
Krystexxa (Pegloticase) August 20, 2010. [cited 01/25/2017]; Available from:
12. Kyrstexxa [package insert]. Glendale, WI: Crealta Pharmaceuticals, Inc.; September 2016.
13. Sundy JS, Baraf HS, Yood RA, et. al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in
patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17;306(7):711-
20. PubMed PMID: 21846852.
14. Khanna D, Fitzgerald JD, Khanna PP, et al.; American College of Rheumatology. 2012 American College of
Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic
therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46. doi:
10.1002/acr.21772. PubMed PMID: 23024028.
15. Spina M, Nagy Z, Ribera JM, et al: FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat
versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at
intermediate to high TLS risk. Ann Oncol 2015; 26(10):2155-2161.
16. Tamura K, Kawai Y, Kiguchi T, et al: Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in
patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing
febuxostat and allopurinol. Int J Clin Oncol 2016; 21(5):996-1003.
17. Gloperba [prescribing information]. Ferndale Laboratories, Inc.; Ferndale, MI; 2019.
History
Date Action and Summary of Changes
03/02/2021 Removed colchicine from policy
11/30/2020 Added link to AHPDL publication
Added language in clinical policy section for cases which do not meet policy
11/12/2020
criteria
08/19/2020 Approved by DUR Board
07/21/2020 Moved dosing lines in criteria to dosing limits section below; added
examples of cardiovascular disease in Uloric criteria;
05/06/2020 Added colchicine (Gloperba)
Policy: Gout Agents Last Updated 03/03/2021
410/01/2019 Removed lesinurad (Zurampic) and lesinurad-allopurinol (Duzallo) due to
product discontinuation by manufacturer
05/31/2019 Updated febuxostat (Uloric) criteria to reflect new black box warning;
updated pegloticase reauthorization criteria; updated background section
02/21/2018 New Policy
Policy: Gout Agents Last Updated 03/03/2021
5You can also read
